Target intelligence / Profile preview

Frizzled class receptor 3 (FZD3)

Target
FZD3
Molecular classification
G protein-coupled receptor (GPCR), Receptor
01

Overview

Frizzled class receptor 3 (FZD3) is a member of the frizzled family of G protein-coupled receptors (GPCRs), characterized by seven transmembrane domains and serving as receptors for Wnt proteins[2][4][1]. FZD3 is critically involved in non-canonical Wnt signaling, particularly planar cell polarity (PCP) pathways that regulate axonal development in the nervous system and neural crest cell migration[1][2][3]. It is also implicated in the canonical β-catenin pathway, with possible roles in hair follicle development and other tissue-specific functions. Disease associations include cancer (notably colorectal cancer), multicystic dysplastic kidney, and genetic susceptibility for schizophrenia[4][1]. Although no approved drugs specifically target FZD3, recent advances include nanobody modulators and characterization of conserved pockets that may be druggable with small molecules[1]. Safety concerns stem from FZD3’s roles in essential developmental and homeostatic processes, raising potential challenges for selective therapeutic intervention.

Other names
Frizzled-3FZD3Fz-3hFz3seven transmembrane spanning receptorfrizzled family receptor 3frizzled homolog 3frizzled 3
02

Mechanism of action

Nanobody modulators can act as antagonists or agonists by competing with Wnt ligands or intracellular effectors (Dishevelled proteins, G protein coupling) Small molecule inhibitors (potential) that block the transmembrane ligand binding groove

03

Biological functions

Signal transduction (Wnt signaling)Regulation of planar cell polarity (PCP)Axonal development and guidance (nervous system)Cell migration (e.g., neural crest cells)Potential role in hair follicle development
04

Disease associations

Cancer (including colorectal cancer, as susceptibility locus)Neurodegenerative/neuropsychiatric disorders (schizophrenia susceptibility)Kidney diseases (multicystic dysplastic kidney)
05

Safety considerations

Targeting Wnt/FZD signaling can affect normal tissue homeostasis, including stem cell renewal, development, and tissue regenerationPotential risk for off-target effects due to widespread expression and functional importance
06

Interacting drugs

Currently, there are no approved drugs directly targeting FZD3, but research molecules such as nanobody modulators, and the small molecule inhibitor F7H for FZD family members (e.g., FZD7, but with conserved binding pockets)
07

Biomarkers

FZD3 protein or mRNA expression may serve as a biomarker in cancers or as a susceptibility marker for schizophrenia

Beyond the preview

Go deeper on Frizzled class receptor 3 (FZD3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Frizzled class receptor 3 (FZD3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call